BioCentury | Jun 23, 2014
Company News

Maxygen Inc other news

...company liquidated and filed a certificate of dissolution last August (see BioCentury, Sept. 2, 2013). Maxygen...
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

...society are immeasurable. The many companies he formed (Alza, Affymax, Alexza, Affymetrix, Dynapol, DNAX, Symyx, Maxygen...
BioCentury | Sep 2, 2013
Company News

Maxygen hematology, other news

...Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve...
...the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen...
...certificate of dissolution. NASDAQ also suspended trading of the stock on Aug. 29 and advised Maxygen...
BioCentury | Jun 17, 2013
Company News

Maxygen hematology, other news

...three-month operating loss of $2.2 million. Maxygen had a 2012 operating gain of $20.3 million. Maxygen's...
...company said it has no plans to independently continue development of MAXY-G34 for either indication. Maxygen Inc....
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

...small molecule kinase-targeted drug discovery for cancer. Perseid was formed under a 2009 JV with Maxygen Inc....
...Genentech Inc. , South San Francisco, Calif. High Energy Accelerator Research Organization , Tsukuba, Japan Maxygen Inc....
...OSI Pharmaceuticals Inc. and the remaining stake in Perseid Therapeutics LLC, a JV with Maxygen Inc....
BioCentury | Apr 15, 2013
Company News

Maxygen management update

Maxygen Inc., Santa Clara, Calif. Business: Enabling technology Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president and scientific...
BioCentury | May 21, 2012
Company News

Maxygen, Bayer deal

...from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's...
...of recombinant Factor VIIa product (formerly MAXY-VII) and after undisclosed patent related conditions were met. Maxygen...
...is not eligible for any further payments under the deal (see BioCentury, July 7, 2008). Maxygen Inc....
BioCentury | May 21, 2012
Finance

Highlights of weekly biotech stock moves

...and €15.2 million ($19.5 million) in a private placement of 6.6 million shares at €2.30. Maxygen Inc....
...milestone payment from Bayer AG (Xetra:BAYN) under a 2008 deal in which the pharma acquired Maxygen's...
BioCentury | Jan 16, 2012
Financial News

Maxygen financial update

...million through Dec. 31. Maxygen, which closed Friday at $5.51, has 28.1 million shares outstanding. Maxygen Inc....
BioCentury | Nov 14, 2011
Company News

Maxygen other news

...and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen...
...overseas manufacturing, uncertain IP issues for MAXY-G34 and the company's reliance on consultants and subcontractors. Maxygen...
...that cover mutated G-CSF molecules, which Maxygen said may cover MAXY-G34 (see BioCentury, Oct. 17). Maxygen Inc....
Items per page:
1 - 10 of 294
BioCentury | Jun 23, 2014
Company News

Maxygen Inc other news

...company liquidated and filed a certificate of dissolution last August (see BioCentury, Sept. 2, 2013). Maxygen...
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

...society are immeasurable. The many companies he formed (Alza, Affymax, Alexza, Affymetrix, Dynapol, DNAX, Symyx, Maxygen...
BioCentury | Sep 2, 2013
Company News

Maxygen hematology, other news

...Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve...
...the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen...
...certificate of dissolution. NASDAQ also suspended trading of the stock on Aug. 29 and advised Maxygen...
BioCentury | Jun 17, 2013
Company News

Maxygen hematology, other news

...three-month operating loss of $2.2 million. Maxygen had a 2012 operating gain of $20.3 million. Maxygen's...
...company said it has no plans to independently continue development of MAXY-G34 for either indication. Maxygen Inc....
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

...small molecule kinase-targeted drug discovery for cancer. Perseid was formed under a 2009 JV with Maxygen Inc....
...Genentech Inc. , South San Francisco, Calif. High Energy Accelerator Research Organization , Tsukuba, Japan Maxygen Inc....
...OSI Pharmaceuticals Inc. and the remaining stake in Perseid Therapeutics LLC, a JV with Maxygen Inc....
BioCentury | Apr 15, 2013
Company News

Maxygen management update

Maxygen Inc., Santa Clara, Calif. Business: Enabling technology Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president and scientific...
BioCentury | May 21, 2012
Company News

Maxygen, Bayer deal

...from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's...
...of recombinant Factor VIIa product (formerly MAXY-VII) and after undisclosed patent related conditions were met. Maxygen...
...is not eligible for any further payments under the deal (see BioCentury, July 7, 2008). Maxygen Inc....
BioCentury | May 21, 2012
Finance

Highlights of weekly biotech stock moves

...and €15.2 million ($19.5 million) in a private placement of 6.6 million shares at €2.30. Maxygen Inc....
...milestone payment from Bayer AG (Xetra:BAYN) under a 2008 deal in which the pharma acquired Maxygen's...
BioCentury | Jan 16, 2012
Financial News

Maxygen financial update

...million through Dec. 31. Maxygen, which closed Friday at $5.51, has 28.1 million shares outstanding. Maxygen Inc....
BioCentury | Nov 14, 2011
Company News

Maxygen other news

...and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen...
...overseas manufacturing, uncertain IP issues for MAXY-G34 and the company's reliance on consultants and subcontractors. Maxygen...
...that cover mutated G-CSF molecules, which Maxygen said may cover MAXY-G34 (see BioCentury, Oct. 17). Maxygen Inc....
Items per page:
1 - 10 of 294